Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores. With increasing lopinavir mutation scores, the proportion of patients achieving a week 48 treatment response was increased in the tipranavir/ritonavir compared with the lopinavir/ritonavir arm. Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir.
Walmsley
Sharon L
SL
Toronto General Hospital, University of Toronto, Toronto, Canada.
Cotte
Laurent
L
Rusconi
Stefano
S
Ward
Douglas J
DJ
Hicks
Charles B
CB
Meier
Ulrich
U
Valdez
Hernan
H
Boucher
Charles Ab
CA
D023241:Antiretroviral Therapy, Highly Active; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D009154:Mutation; D011725:Pyridines / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D011753:Pyrones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000627:therapeutic use*; D013449:Sulfonamides; D016896:Treatment Outcome; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011744:Pyrimidinones; D011753:Pyrones; D012367:RNA, Viral; D013449:Sulfonamides; D061466:Lopinavir; D016333:HIV Protease; D019438:Ritonavir; C107201:tipranavir